María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
CRISPR Enters First Human Clinical Trials in the U.S.
Researchers in the U.S. have started using CRISPR/Cas9 to edit genes in adults with genetic diseases such as sarcoma, myeloma, sickle cell disease, and...
FDA Approves Fedratinib for Myelofibrosis
The U.S. Food and Drug Administration (FDA) has approved fedratinib to treat intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Previously,...
U.S. Task Force Recommends Doctors Ask Adults About Illicit Drug Use
The U.S. Preventive Services Task Force (USPSTF), an independent panel of medical experts, released a draft recommendation that advised doctors to ask all patients...
NIH’s Cancer Moonshot Program to Require Immediate Open Access to Funded Research
The Cancer Moonshot program at the National Cancer Institute (NCI), a program launched in 2016 and spearheaded by then Vice President Joe Biden, has...
Just 15% of Pharmacies Distributed Half of the Opioids in the U.S.
At the height of the opioid epidemic, thousands of small, family-owned pharmacies handled huge volumes of hydrocodone and oxycodone, according to a report from...
Current Issue
August 2019, Volume 5, Issue 10
This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.
